Performance of a proteomic preterm delivery predictor in a large independent prospective cohort.

IGFBP4 biomarker insulin-like growth factor-binding protein 4 neonatal morbidity and mortality pregnancy prematurity preterm birth proteomics sex hormone-binding globulin

Journal

American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609

Informations de publication

Date de publication:
08 2020
Historique:
received: 23 03 2020
revised: 05 05 2020
accepted: 06 05 2020
entrez: 21 12 2020
pubmed: 22 12 2020
medline: 25 6 2021
Statut: ppublish

Résumé

Preterm birth remains a common and devastating complication of pregnancy. There remains a need for effective and accurate screening methods for preterm birth. Using a proteomic approach, we previously discovered and validated (Proteomic Assessment of Preterm Risk study, NCT01371019) a preterm birth predictor comprising a ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin. To determine the performance of the ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin to predict both spontaneous and medically indicated very preterm births, in an independent cohort distinct from the one in which it was developed. This was a prospective observational study (Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor, NCT02787213) at 18 sites in the United States. Women had blood drawn at 17 A total of 5011 women were enrolled, with 847 included in this planned substudy analysis. There were 9 preterm birth cases at <32 We confirmed in an independent cohort the ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin ratio as a predictor of very preterm birth, with additional prediction of increased length of neonatal hospital stay and increased severity of adverse neonatal outcomes. Potential uses of the ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin predictor may be to risk stratify patients for implementation of preterm birth preventive strategies and direct patients to appropriate levels of care.

Sections du résumé

BACKGROUND
Preterm birth remains a common and devastating complication of pregnancy. There remains a need for effective and accurate screening methods for preterm birth. Using a proteomic approach, we previously discovered and validated (Proteomic Assessment of Preterm Risk study, NCT01371019) a preterm birth predictor comprising a ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin.
OBJECTIVE
To determine the performance of the ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin to predict both spontaneous and medically indicated very preterm births, in an independent cohort distinct from the one in which it was developed.
STUDY DESIGN
This was a prospective observational study (Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor, NCT02787213) at 18 sites in the United States. Women had blood drawn at 17
RESULTS
A total of 5011 women were enrolled, with 847 included in this planned substudy analysis. There were 9 preterm birth cases at <32
CONCLUSION
We confirmed in an independent cohort the ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin ratio as a predictor of very preterm birth, with additional prediction of increased length of neonatal hospital stay and increased severity of adverse neonatal outcomes. Potential uses of the ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin predictor may be to risk stratify patients for implementation of preterm birth preventive strategies and direct patients to appropriate levels of care.

Identifiants

pubmed: 33345877
pii: S2589-9333(20)30084-7
doi: 10.1016/j.ajogmf.2020.100140
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02787213']

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100140

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Glenn R Markenson (GR)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Boston Medical Center, Boston, MA.

George R Saade (GR)

Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX.

Louise C Laurent (LC)

Division of Maternal-Fetal Medicine, Department of Reproductive Sciences, University of California, San Diego, CA.

Kent D Heyborne (KD)

Department of Obstetrics and Gynecology, Denver Health and Hospital Authority.

Dean V Coonrod (DV)

Department of Obstetrics and Gynecology, Maricopa Integrated Health System.

Corina N Schoen (CN)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Massachusetts-Baystate.

Jason K Baxter (JK)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Thomas Jefferson University Hospital.

David M Haas (DM)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Indiana University.

Sherri Longo (S)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Ochsner Baptist Medical Center, New Orleans, LA.

William A Grobman (WA)

Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL.

Scott A Sullivan (SA)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC.

Carol A Major (CA)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of California, Irvine, CA.

Sarahn M Wheeler (SM)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University, Durham, NC.

Leonardo M Pereira (LM)

Division Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR.

Emily J Su (EJ)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO.

Kim A Boggess (KA)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC.

Angela F Hawk (AF)

Regional Obstetrical Consultants, Chattanooga, TN.

Amy H Crockett (AH)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Greenville Health System, Greenville, SC.

Angela C Fox (AC)

Sera Prognostics, Salt Lake City, UT.

Ashoka Polpitiya (A)

Sera Prognostics, Salt Lake City, UT.

Tracey C Fleischer (TC)

Sera Prognostics, Salt Lake City, UT.

Gregory C Critchfield (GC)

Sera Prognostics, Salt Lake City, UT.

Julja Burchard (J)

Sera Prognostics, Salt Lake City, UT.

J Jay Boniface (JJ)

Sera Prognostics, Salt Lake City, UT.

Garrett K Lam (GK)

Sera Prognostics, Salt Lake City, UT. Electronic address: glam103@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH